

COPY OF PAPERS
ORIGINALLY FILEDPatent
231/003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Thomas Kipps et al.

Serial No.: 08/982,272

Filed: December 1, 1997

For: NOVEL EXPRESSION VECTORS
CONTAINING ACCESSORY
MOLECULE LIGAND GENES AND
THEIR USE FOR
IMMUNOMODULATION AND
TREATMENT OF MALIGNANCIES
AND AUTOIMMUNE DISEASE

Group Art Unit: 1644

Examiner: P. Gambel

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

AUG 21 2002

TECH CENTER 1600/2900

AMENDMENT TRANSMITTAL

Box Fee Amendment
Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is an Amendment and Response for the above-identified application.

- ☒ Applicant(s) petitions for an extension of time under 37 CFR § 1.136 [fees: 37 CFR § 1.17(a)(1)-(5)] for the total number of months checked below:

EXTENSION (months)	FEE FOR SMALL ENTITY	FEE FOR OTHER THAN SMALL ENTITY
1 month	<input type="checkbox"/> \$55.00	<input type="checkbox"/> \$110.00
2 months	<input checked="" type="checkbox"/> \$200.00	<input type="checkbox"/> \$400.00
3 months	<input type="checkbox"/> \$460.00	<input type="checkbox"/> \$920.00
4 months	<input type="checkbox"/> \$720.00	<input type="checkbox"/> \$1,440.00
5 months	<input type="checkbox"/> \$980.00	<input type="checkbox"/> \$1,960.00

08/20/2002 DTESSEM1 00000083 122475 08982272

01 FC:216 200.00 FH

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

August 14, 2002
Date of Deposit

Linda Johnson

Name of Person Mailing Paper

Signature of Person Mailing Paper

- ☐ An extension for _____ months has already been secured and the fee paid therefor of _____ is deducted from the total fee due for the total months of extension now requested.
- ☒ Extension fee due with this Request \$200.00.
- ☒ If an additional extension of time is required, please consider this a petition therefor.

FEES FOR CLAIMS:

- ☒ Applicant claims small entity status pursuant to 37 CFR 1.27.

The fees for claims (37 CFR § 1.16(b)-(d)) have been calculated as shown below:

Total Claims	47	-	50	=	0	x	\$18.00	\$0.00
Independent Claims	7	-	7	=	0	x	\$84.00	\$0.00
Multiple Dependent Claims	\$280	(if applicable)					<input type="checkbox"/>	\$0.00
TOTAL OF ABOVE CALCULATIONS								\$0.00
Reduction by ½ for Filing by Small Entity. Note 37 CFR §§ 1.9, 1.27, 1.28.								<input checked="" type="checkbox"/> \$0.00
TOTAL FEES FOR CLAIMS SUBMITTED HEREWITH								\$0.00

- ☐ A check in the amount of _____ is enclosed to cover the above fee(s).
- ☒ Charge Lyon & Lyon's Deposit Account No. **12-2475** in the amount of \$200.00.

- ☒ The Commissioner is authorized to charge Lyon & Lyon's Deposit Account No. **12-2475** for any fees required under 37 CFR §§ 1.16 and 1.17 that are not covered, in whole or in part, by a check enclosed herewith and to credit any overpayments to said Deposit Account **12-2475**.

Respectfully submitted,

LYON & LYON LLP

Dated: August 14, 2002

By: *Rita A. Abbati*

Rita A. Abbati
Reg. No. 50,715

633 West Fifth Street
Suite 4700
Los Angeles, CA 90071-2066
(858) 552-8400



1644
Patent
231/003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Thomas Kipps, et al.

Serial No.: 08/982,272

Filed: December 1, 1997

For: NOVEL EXPRESSION VECTORS
CONTAINING ACCESSORY
MOLECULE LIGAND GENES AND
THEIR USE FOR
IMMUNOMODULATION AND
TREATMENT OF MALIGNANCIES
AND AUTOIMMUNE DISEASE

Group Art Unit: 1644 29/E

Examiner: P. Gambel

RECEIVED

AUG 21 2002

TECH CENTER 1600/2900

AMENDMENT AND RESPONSE

COPY OF PAPERS
ORIGINALLY FILED

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated May 31, 2002, please consider the following amendments and remarks.

Amendment

In the claims:

Please amend claim 111 as follows:

2x500x5
111. (Twice Amended) The method of claims 89, 90, 103, 108, 137 or 138,
wherein the cell comprises a human neoplastic cell that is CD40+.